Literature DB >> 29967021

Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence.

Yiying Cai1,2, Celene L Seah2, Hui Leck1, Tze-Peng Lim1, Jocelyn Q Teo1,3, Winnie Lee1, Thuan-Tong Tan4, Tse-Hsien Koh5, Pui Lai Rachel Ee2, Andrea L Kwa6,2,7.   

Abstract

To guide the timely selection of antibiotic combinations against carbapenem-resistant Gram-negative bacteria (CR-GNB), an in vitro test with a short turnaround time is essential. We developed an in vitro ATP bioluminescence assay to determine effective antibiotic combinations against CR-GNB within 6 h. We tested 42 clinical CR-GNB strains (14 Acinetobacter baumannii, 14 Pseudomonas aeruginosa, and 14 Klebsiella pneumoniae strains) against 74 single antibiotics and two-antibiotic combinations. Bacteria (approximately 5 log10 CFU/ml) were incubated with an antibiotic(s) at 35°C; ATP bioluminescence was measured at 6 h and 24 h; and the measurements were compared to viable counts at 24 h. Receiver operating characteristic (ROC) curves were used to determine the optimal luminescence thresholds (TRLU) for distinguishing between inhibitory and noninhibitory combinations. The areas under the 6-h and 24-h ROC curves were compared using the DeLong method. Prospective validation of the established thresholds was conducted using 18 additional CR-GNB. The predictive accuracy of TRLU for the 6-h ATP bioluminescence assay was 77.5% when all species were analyzed collectively. Predictive accuracies ranged from 73.7% to 82.7% when each species was analyzed individually. Upon comparison of the areas under the 6-h and 24-h ROC curves, the 6-h assay performed significantly better than the 24-h assay (P < 0.01). Predictive accuracy remained high upon prospective validation of the 6-h ATP assay (predictive accuracy, 79.8%; 95% confidence interval [CI], 77.6 to 81.9%), confirming the external validity of the assay. Our findings indicate that our 6-h ATP bioluminescence assay can provide guidance for prospective selection of antibiotic combinations against CR-GNB in a timely manner and may be useful in the management of CR-GNB infections.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  in vitro combination testing; luciferin-luciferase reaction; multidrug resistance

Mesh:

Substances:

Year:  2018        PMID: 29967021      PMCID: PMC6125559          DOI: 10.1128/AAC.00183-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Development of a rapid ATP bioluminescence assay for biocidal susceptibility testing of rapidly growing mycobacteria.

Authors:  Renuka Kapoor; Jagjit S Yadav
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  A comparison of three rapid and accurate bioluminescent antibiotic susceptibility tests.

Authors:  Mickael Lafond; Nicolas Vidal; Yves Letourneux; Jean Michel Brunel
Journal:  J Pharmacol Toxicol Methods       Date:  2009-10-25       Impact factor: 1.950

4.  A set of multiplex PCRs for genotypic detection of extended-spectrum β-lactamases, carbapenemases, plasmid-mediated AmpC β-lactamases and OXA β-lactamases.

Authors:  Guido M Voets; A C Fluit; Jelle Scharringa; James Cohen Stuart; Maurine A Leverstein-van Hall
Journal:  Int J Antimicrob Agents       Date:  2011-02-25       Impact factor: 5.283

5.  Rapid antibiotic susceptibility tests on Enterobacteriaceae by ATP bioluminescence.

Authors:  P F Wheat; J G Hastings; R C Spencer
Journal:  J Med Microbiol       Date:  1988-02       Impact factor: 2.472

6.  Modelling time-kill studies to discern the pharmacodynamics of meropenem.

Authors:  Vincent H Tam; Amy N Schilling; Michael Nikolaou
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

7.  Novel antibiotic susceptibility tests by the ATP-bioluminescence method using filamentous cell treatment.

Authors:  N Hattori; M O Nakajima; K O'Hara; T Sawai
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 8.  Combination therapy for carbapenem-resistant Gram-negative bacteria.

Authors:  Alexandre P Zavascki; Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091

9.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 10.  Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot.

Authors:  Jocelyn Qi Min Teo; Yiying Cai; Tze-Peng Lim; Thuan Tong Tan; Andrea Lay-Hoon Kwa
Journal:  Microorganisms       Date:  2016-02-16
View more
  3 in total

1.  Predictors of Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacilli or Vancomycin-Resistant Enterococci Bacteremia.

Authors:  Hye Jin Shi; Jin Seo Lee; Yong Kyun Cho; Joong Sik Eom
Journal:  Infect Drug Resist       Date:  2020-10-09       Impact factor: 4.003

2.  Real-time monitoring of extracellular ATP in bacterial cultures using thermostable luciferase.

Authors:  Julian Ihssen; Nina Jovanovic; Teja Sirec; Urs Spitz
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

3.  ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa.

Authors:  Berta Puig-Collderram; Sandra Domene-Ochoa; Maria Salvà-Comas; Maria Milagro Montero; Xavier Duran; Juan R González; Santiago Grau; Antonio Oliver; Juan P Horcajada; Eduardo Padilla; Concepción Segura; Núria Prim
Journal:  Microbiol Spectr       Date:  2022-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.